idarubicinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

idarubicinol: RN given refers to (7S-(7alpha,9alpha,9(R*))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	21118312
CHEBI ID	197279
SCHEMBL ID	13147738
MeSH ID	M0153726

Synonyms (7)

Synonym
idarubicinol
(7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(1s)-1-hydroxyethyl]-8,10-dihydro-7h-tetracene-5,12-dione
CHEBI:197279
z3gyr877xq ,
SCHEMBL13147738
(9s)-7-((2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyltetrahydro-2h-pyran-2-yloxy)-6,9,11-trihydroxy-9-((s)-1-hydroxyethyl)-7,8,9,10-tetrahydrotetracene-5,12-dione
(7s,9s)-7-[(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-9-[(1r*)-1-hydroxyethyl]-5,12-naphthacenedione

Research Excerpts

Pharmacokinetics

The ratio of the areas under the curve (0-24) idarubicinol/idarubICin increased from day to day. Due to its protracted half-life (64 hr) this metabolite progressively accumulated.

Excerpt	Reference	Relevance
" The IDAol terminal half-life and mean residence time (MRT) were significantly increased in patients with impaired kidney function [MRT: group N, 63."	( Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Camaggi, CM; Carisi, P; Efthymiopoulos, C; Guaraldi, M; Martoni, A; Pannuti, F; Strocchi, E; Strolin-Benedetti, M; Tononi, A, 1992)	0.28
" Due to its protracted half-life (64 hr in this study), this metabolite progressively accumulated and the ratio of the areas under the curve (0-24) idarubicinol/idarubicin increased from day to day."	( Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J, 1990)	0.28
" There was substantial variability in idarubicin elimination among patients, but no indication of dose-dependent or of schedule-dependent changes in pharmacokinetic parameters."	( Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Ames, MM; Hammond, GD; Krailo, MD; Pendergrass, TW; Reid, JM, 1990)	0.28
" No correlation was found between the pharmacokinetic parameters and the time to final progression."	( Pharmacokinetics of oral idarubicin in breast cancer patients with reference to antitumor activity and side effects. Bastholt, L; Dalmark, M; Ebbehøj, E; Elbaek, K; Jakobsen, A; Juul, P; Rasmussen, SN; Steiness, E, 1989)	0.28
" For unchanged idarubicin, similar pharmacokinetic parameters were exhibited after the 1st and the 5th injection."	( Pharmacokinetics of idarubicin after daily intravenous administration in leukemic patients. Harousseau, JL; Huet, S; Hurteloup, P; Pris, J; Reiffers, J; Rigal-Huguet, F; Robert, J; Tamassia, V, 1987)	0.27
" Although idarubicin was given in one-fifth of the dose, the intracellular peak concentration was 70% of that of daunorubicin."	( Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia. Paul, C; Sundman-Engberg, B; Tidefelt, U, 1994)	0.29
" The average terminal half-life was 30."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1996)	0.29
" The plasma concentration time course of Ida was most properly described by the three-compartment pharmacokinetic model, independent of administration time."	( Plasma pharmacokinetics of idarubicin and its 13-dihydro metabolite--a comparison of bolus versus 2 h infusion during a 3 day course. Björkholm, M; Eksborg, S; Fagerlund, E; Hast, R, 1997)	0.3
" The average terminal half-life was 30."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1997)	0.3
" With respect to cellular resistance mechanisms, 2 different pharmacodynamic phases can be distinguished: intracellular distribution and cellular reaction."	( Intracellular pharmacokinetics of anthracyclines in human leukemia cells: correlation of DNA-binding with apoptotic cell death. Brieden, T; Gieseler, F; Kunze, J; Nüssler, V; Valsamas, S, 1998)	0.3
" Various pharmacokinetic profiles, with and without clinically relevant peak concentrations, were simulated in vitro."	( Induction of apoptosis by idarubicin: how important is the plasma peak? Clark, M; Gieseler, F; Puschmann, M; Stiebeling, K; Valsamas, S, 2000)	0.31
" We simulated a bolus application and a continuous infusion using two different pharmacokinetic profiles of idarubicin with comparable AUCs (area under the time curve)."	( Induction of apoptosis by idarubicin: how important is the plasma peak? Clark, M; Gieseler, F; Puschmann, M; Stiebeling, K; Valsamas, S, 2000)	0.31
"To clarify the pharmacokinetic properties of idarubicin (IDA) in Japanese patients and to clarify the relationship between the pharmacokinetic parameters of IDA or idarubicinol (IDAol), an active metabolite of IDA, and leukocytopenia or neutropenia, we examined the pharmacokinetics of IDA in patients with malignant lymphoma."	( A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia. Fukushima, T; Goto, N; Kuraishi, Y; Ogawa, M; Ohno, R; Okabe, KI; Ueda, T; Urabe, A; Yamashita, T, 2001)	0.31
" The plasma concentration-time data were analysed, assuming a biexponential disposition curve, both by the traditional (two-stage) method and by population pharmacokinetic modelling."	( Pharmacokinetics and toxicity of idarubicin in the rat. Hofmann, S; Kuhlmann, O; Weiss, M, )	0.13
" The pharmacokinetic parameters of idarubicin found after duodenal administration of the two formulations were different: area under the curve of concentration versus time (AUC) and elimination half-life were approximately 21 times and 30 times, respectively, higher after IDA-SLN administration than after the solution administration."	( Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. Bargoni, A; Cavalli, R; Fundarò, A; Gasco, MR; Vighetto, D; Zara, GP, 2002)	0.31

Compound-Compound Interactions

Excerpt	Reference	Relevance
" In this work we compared in vitro the effects of IDA and 2HIDA used alone and in combination with 2 microM cyclosporin A (CyA) in the MDR leukemic cell lines FLCR and K562R and in their sensitive parent cell lines FLC and K562."	( Comparative activity of idarubicin and idarubicinol in combination with cyclosporin A in multidrug-resistant leukemia cells. Abbadessa, V; Cajozzo, A; Gancitano, RA; Musso, M; Perricone, R; Porretto, F; Tolomeo, M, 1996)	0.29

Bioavailability

Excerpt	Reference	Relevance
" administration of the drug in another study, the bioavailability of idarubicin alone can be estimated to about 21%, whereas the bioavailability of the sum idarubicin + idarubicinol is about 41%."	( Pharmacokinetics of idarubicin after oral administration in elderly leukemic patients. Huet, S; Hurteloup, P; Pris, J; Rigal-Huguet, F; Robert, J, 1990)	0.28
" dose, and the bioavailability of the oral dose ranged between 9% and 39%."	( Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. D'Incalci, M; Erranti, D; Freshi, A; Tirelli, U; Zanette, L; Zucchetti, M, 1990)	0.28
" These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under the curve values (AUC) for an appropriate adjustment of idarubicin dose."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1996)	0.29
" These perspectives are somewhat hampered by the large variation in bioavailability between individual patients and the obvious requirement to monitor plasma concentration and area-under-the-curve values (AUC) for an appropriate adjustment of idarubicin dose."	( Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curve. Braess, J; Hiddemann, W; Kaufmann, CC; Kern, W; Kühn, S; Rührs, H; Schleyer, E; Sträubel, G; Unterhalt, M, 1997)	0.3
" The aim of this research was to study whether the bioavailability of idarubicin can be improved by administering IDA-SLN duodenally to rats."	( Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats. Bargoni, A; Cavalli, R; Fundarò, A; Gasco, MR; Vighetto, D; Zara, GP, 2002)	0.31

Dosage Studied

Excerpt	Relevance	Reference
"We evaluated in vitro the toxicity of idarubicin and its active metabolite idarubicinol on haematopoietic progenitors, using human umbilical cord blood and peripheral blood progenitors to obtain dose-response curves."	( Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. Cocorocchio, E; Corsini, C; D'Incalci, M; Ferrucci, PF; Ghielmini, M; Mancuso, P; Martinelli, G; Mezzetti, M; Mori, A; Paolucci, M; Riggi, M; Tealdo, F; Zucchetti, M, 2000)	0.31

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

Class	Description
anthracycline	Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (51)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	5 (9.80)	18.7374
1990's	31 (60.78)	18.2507
2000's	15 (29.41)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	10 (18.52%)	5.53%
Reviews	1 (1.85%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	43 (79.63%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	2.01	1	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	2.7	3	0	aromatic ether; nitrile; polyether; tertiary amino compound
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	3.39	1	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
ifosfamide [no description available]	3.38	1	1	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	7.01	1	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
potassium chloride Potassium Chloride: A white crystal or crystalline powder used in BUFFERS; FERTILIZERS; and EXPLOSIVES. It can be used to replenish ELECTROLYTES and restore WATER-ELECTROLYTE BALANCE in treating HYPOKALEMIA.. potassium chloride : A metal chloride salt with a K(+) counterion.	2.03	1	0	inorganic chloride; inorganic potassium salt; potassium salt	fertilizer
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	2.01	1	0	aziridines
phenylephrine Phenylephrine: An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent.. phenylephrine : A member of the class of the class of phenylethanolamines that is (1R)-2-(methylamino)-1-phenylethan-1-ol carrying an additional hydroxy substituent at position 3 on the phenyl ring.	2.03	1	0	phenols; phenylethanolamines; secondary amino compound	alpha-adrenergic agonist; cardiotonic drug; mydriatic agent; nasal decongestant; protective agent; sympathomimetic agent; vasoconstrictor agent
cytarabine [no description available]	3.37	1	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
deoxycytidine [no description available]	2.01	1	0	pyrimidine 2'-deoxyribonucleoside	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	10.7	51	10	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	3.8	2	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.38	1	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	4.47	5	1	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	9.6	47	9	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
adriamycinol doxorubicinol : A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties.	2.38	2	0	aminoglycoside; anthracycline antibiotic; aromatic ether; deoxy hexoside; p-quinones; phenols; polyol; tetracenequinones	cardiotoxic agent; drug metabolite
4'-deoxy-4'-iododoxorubicin 4'-deoxy-4'-iododoxorubicin: lipophilic derivative of doxorubicin which differs from the parent compound in substitution of hydroxyl group on the daunosamine sugar moiety	1.97	1	0	organoiodine compound; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
methotrexate [no description available]	3.39	1	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	3.39	1	1	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
dihydropyridines Dihydropyridines: Pyridine moieties which are partially saturated by the addition of two hydrogen atoms in any position.	2	1	0
daunorubicinol daunorubicinol: main metabolite of daunomycin. (13S)-13-dihydrodaunorubicin : The (13S)-diastereomer of 13-dihydrodaunorubicin.	3.08	5	0	13-dihydrodaunorubicin
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	2.01	1	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
rutin Hydroxyethylrutoside: Monohydroxyethyl derivative of rutin. Peripheral circulation stimulant used in treatment of venous disorders.	7.01	1	0	disaccharide derivative; quercetin O-glucoside; rutinoside; tetrahydroxyflavone	antioxidant; metabolite
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	2.41	2	0	homodetic cyclic peptide
dexniguldipine niguldipine: structure given in first source; clinical modulator of multidrug resistance	2	1	0	diarylmethane
4'-iodo-4'-deoxydoxorubicinol 4'-iodo-4'-deoxydoxorubicinol: structure given in first source	1.97	1	0
cyclosporine Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).	2.68	3	0
trypan blue Trypan Blue: A diazo-naphthalene sulfonate that is widely used as a stain.. trypan blue : An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid).	1.99	1	0

Condition	Relationship Strength	Studies	Trials
Disease Exacerbation [description not available]	2.01	1	0
Breast Cancer [description not available]	10.33	7	2
Metastase [description not available]	3.8	2	1
Breast Neoplasms Tumors or cancer of the human BREAST.	5.33	7	2
Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.	3.8	2	1
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	5.04	5	2
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	5.04	5	2
Acute Lymphoid Leukemia [description not available]	4.7	2	1
Ph 1 Chromosome [description not available]	4.32	1	1
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	4.7	2	1
Bone Cancer [description not available]	3.41	1	1
Cancer of Liver [description not available]	4.35	2	2
Cancer of Lung [description not available]	3.41	1	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	3.41	1	1
Liver Neoplasms Tumors or cancer of the LIVER.	4.35	2	2
Lung Neoplasms Tumors or cancer of the LUNG.	3.41	1	1
Soft Tissue Neoplasms Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.	3.41	1	1
Granulocytic Leukemia [description not available]	4.47	5	1
Leukemia, Myeloid Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.	4.47	5	1
Acute Disease Disease having a short and relatively severe course.	4.29	4	1
Acute Myelogenous Leukemia [description not available]	5.31	7	2
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	5.31	7	2
Leucocythaemia [description not available]	3.77	2	1
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	8.77	2	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2	1	0
ATLL [description not available]	2	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2	1	0
Leukemia-Lymphoma, Adult T-Cell Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.	2	1	0
Blast Phase [description not available]	2	1	0
Blast Crisis An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.	2	1	0
Granuloma, Hodgkin [description not available]	2	1	0
Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.	2	1	0
Acute Promyelocytic Leukemia [description not available]	2	1	0
Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION.	2	1	0
Recrudescence [description not available]	2	1	0
Leukocytopenia [description not available]	3.39	1	1
Germinoblastoma [description not available]	3.39	1	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	3.39	1	1
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	3.39	1	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	3.39	1	1
Glial Cell Tumors [description not available]	2.38	2	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.38	2	0
Benign Neoplasms [description not available]	3.77	2	1
Kidney Diseases Pathological processes of the KIDNEY or its component tissues.	3.36	1	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.77	2	1
Carcinoma, Anaplastic [description not available]	1.97	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	1.97	1	0

chemdatabank.com